Amicus Therapeutics Inc

Amicus Therapeutics — Q2 2020 Earnings Presentation

23 slides from Amicus Therapeutics's earnings presentation, Aug 10, 2020

  1. Slide 1: Amicus Therapeutics 2Q20 Financial Results Conference Call & Webcast

    Amicus | Therapeutics’ | | 2Q20 Financial Results Conference Call & Webcast August 10, 2020

  2. Slide 2: Forward-Looking Statements

    Introduction 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinica

  3. Slide 3: A leading fully integrated, global rare disease biotechnology company

    Introduction 3 A leading fully integrated, global rare disease biotechnology company Gene Therapy PLATFORM Protein Engineering & Glycobiology World Class BIOLOGICS Capabilities EMPL YEES in 27 Countries AT-GAA Phase 3 in Pompe Disease GLOBAL Robust R&D Engine Nearly 50+ Lysosomal Disorders and More

  4. Slide 4: 2020 Key Strategic Priorities

    Introduction 4 2020 Key Strategic Priorities 1Achieve global product revenue for Galafold of $250M-$260M 2 3 4 5Maintain strong financial position

  5. Slide 5: Galafold Global Launch

    Galafold®(migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease - - Amicus Belief Statement

  6. Slide 6: Galafold: Precision Medicine for Fabry Disease

    Galafold: Precision Medicine for Fabry Disease 6 Galafold Snapshot (as of June 30, 2020) Galafold is an orally delivered small molecule precision medicine with a unique mechanism of action for Fabry patients with amenable variants that replaces the need for intravenously delivered enzyme replacement

  7. Slide 7: Galafold Quarterly Performance

    Galafold: Precision Medicine for Fabry Disease 7 Galafold Quarterly Performance Growth remains steady with Q2 revenue of $62.4M, or $63.3M on a constant currency basis Quarterly Galafold Sales Year-over-Year Galafold Sales Growth $44.1M $48.8M $55.3M $60.5M $62.4M +43% -2% $62.4M $44.1M 2Q19 3Q19 4Q

  8. Slide 8: Galafold Growth Trajectory

    Galafold: Precision Medicine for Fabry Disease 8 Galafold Growth Trajectory Galafold is on track to generate $1B+ in projected cumulative revenues from 2020-2022 and is on an anticipated path to $500M+ in annual sales in 2023 and $1B+ annual sales at peak $91M$182M $250M-$260M $500M+ $1B Annual Reve

  9. Slide 9: AT-GAA: Next Potential Standard of Care for Pompe Disease

    AT-GAA:Next Potential Standard of Care for Pompe Disease - - Amicus Belief Statement

  10. Slide 10: AT-GAA: Foundation in Protein Engineering

    AT-GAA for Pompe Disease 10 AT-GAA: Foundation in Protein Engineering Amicus scientists specializing in protein engineering and glycobiology created a uniquely glycosylated and highly phosphorylated ERT (AT-GAA) that significantly enhances targeting to key muscles affected in patients

  11. Slide 11: Preclinical Findings: Differentiated Impact on Pathogenic Cascade

    AT-GAA for Pompe Disease 11 Preclinical Findings: Differentiated Impact on Pathogenic Cascade Meena et. al. 2020 (Independent 5-month AT-GAA study in GAA knockout mice) AT-GAA completely reversed glycogen accumulation and significantly improved a cascade of secondary abnormalities including autophag

  12. Slide 12: AT-GAA: Key Takeaways

    AT-GAA for Pompe Disease 12 AT-GAA: Key Takeaways •PROPEL study timelines are on track with data expected 1H2021 AT-GAA for Pompe Advances Toward Approval as “Crown Jewel” of Amicus Portfolio –To date, 97%+ of the 2,810 planned infusions and assessments for the ongoing PROPEL study have been complet

  13. Slide 13: Next Generation Gene Therapy Platform

    Next Generation Gene TherapyPlatform - - Amicus Belief Statement

  14. Slide 14: Next Generation Gene Therapy Platform Pipeline

    Next Generation Gene Therapy Platform 14 Fabry Franchise Galafold®(migalastat) Monotherapy ODD DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Gene TherapyPENN Pompe Franchise AT-GAA (Novel ERT + Chaperone) ODD Pompe Gene TherapyPENN Batten Franchise – Gene Therapies CLN6 Batten

  15. Slide 15: Gene Therapy: Updates & Key Takeaways

    Next Generation Gene Therapy Platform 15 Gene Therapy: Updates & Key Takeaways Portfolio of Gene Therapy Programs and Technologies Provides Foundation for Future •CLN6 Phase 1/2 interim data show positive impact with potential to become first ever approved gene therapy for fatal brain disease in chi

  16. Slide 16: Combines Amicus and Penn Expertise Across Lysosomal and Rare Diseases

    Next Generation Gene Therapy Platform 16 Combines Amicus and Penn Expertise Across Lysosomal and Rare Diseases An R&D platform with rights to 50+ diseases Protein Engineering & Glycobiology Expertise Clinical and Regulatory Expertise Global Commercial Infrastructure Next-Generation Gene Therapy Plat

  17. Slide 17: Financial Summary

    Financial Summary “We are business led and science driven” - Amicus Belief Statement

  18. Slide 18: 2Q2020 Select Financial Results

    Financial Summary 18 2Q2020 Select Financial Results 2Q2020 revenue of $62.4M primarily from global Galafold sales Jun. 30, 2020 (in thousands, except per share data) Jun. 30, 2019

  19. Slide 19: Financial Outlook: Key Takeaways

    Financial Summary 19 Financial Outlook: Key Takeaways •Proceeds from recent debt facility places Amicus firmly on a path to profitability – Achieved through continued careful expense management, prioritization of very early stage research programs and more measured capital expenditures •Current cash

  20. Slide 20: Closing Remarks

    ClosingRemarks “We are business led and science driven” - Amicus Belief Statement

  21. Slide 21: Thank You

    Thank You “Our passion for making a difference unites us” -Amicus Belief Statement Amicus Therapeutics

  22. Slide 22: Amicus Therapeutics

    La Amicus Therapeutics

  23. Slide 23: Appendix: Reconciliation of Non-GAAP Financial Measures

    Appendix Reconciliation Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) Three Months Ended June 30, ‘Six Months Ended June 30, 2020 2019 2020 2019 Total operating expenses -as reported GAAP S 107032 5 115,93 3 23908 5 226463 Research and development: ‘Share-bas

Amicus Therapeutics — Q2 2020 Earnings Presentation on 6ix